Investigators conducted a study to explore the determinants of HPV vaccine uptake among young women in the U.S. to help produce more effective interventions strategies.

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Routman, during a dedicated poster session ... therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal ...

The company will also present a poster on randomized Phase II data ... TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead asset, with ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026 ...

TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026 ...

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune ...

The event was marked with a poster making and slogan writing competition ... world by sensitising people about the importance of HPV Vaccination and regular screening to prevent Cervical Cancer ...

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March ...

The company will also present a poster on randomized Phase II data of TG4001 in combination ... TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead ...

Partnering with dental clinics to offer HPV vaccines to eligible children and adolescents improved vaccination rates by more ...